【摘要】 目的探讨胰岛素样生长因子(IGF)结合蛋白2,3(IGFBP-2,-3)在卵巢上皮性癌(简称卵巢癌)患者血液和卵巢肿瘤组织中的表达,及其与卵巢癌临床病理学特征的关系。方法采用Western ligand blot和Western blot检测卵巢肿瘤患者及正常对照者(卵巢良性肿瘤10例,交界性肿瘤6例,卵巢癌10例,正常对照者10例)血清中IGFBP-2、IGFBP-3及IGF-Ⅱ含量;免疫组织化学染色检测正常卵巢组织(4例)和卵巢肿瘤组织中(卵巢良性肿瘤8例,卵巢交界性肿瘤8例,卵巢癌23例,包括中度和高度分化者15例,低度分化者8例)IGFBP-2,-3的表达。结果卵巢癌患者血清大片段以及成熟IGF-Ⅱ均明显降低,IGFBP-2水平明显升高,而IGFBP-3含量明显降低甚至消失,与相应正常对照组、良性或交界性组相比差异均有统计学意义(P<0.001或P<0.01)。免疫组织化学染色结果显示卵巢癌IGFBP-2的表达明显升高(P<0.0001或P<0.005),且随着卵巢癌组织分化程度的降低,IGFBP-2的表达呈增强趋势;而IGFBP-3的表达随着卵巢癌细胞分化程度的降低,明显降低或呈阴性表达(P<0.05)。结论卵巢癌患者血循环中IGFBP-3降解以及IGFBP-2明显升高的状况有可能导致IGF-Ⅱ生物学功能改变,并与卵巢癌的临床病理学特征有明显的相关性。更多还原

【Abstract】 Objective To explore the serum levels of IGFBP-2,-3 and their proper roles in the regulation of IGF-Ⅱ bioavailability in patients with ovarian tumor,and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics. Methods Serum levels of IGFBP-2,-3 and big/mature IGF-Ⅱ were measured by Western ligand blot (WLB) and Western blot(WB) in patients with ovarian tumor (10 cases of benign tumor,6 cases of borderline tumor and 10 cases of malignant tumor) and 10 cases of normal control. The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor (8 cases of benign tumor,8 cases of borderline tumor and 23 cases of malignant tumor) and 4 cases of normal ovarian tissues by immunohistochemical staining. Results The serum levels of both big and mature IGF-Ⅱ in epithelial ovarian cancer (ovarian cancer) patients were significantly decreased compared with those of normal control and benign and borderline tumor(P<0.001 or P<0.01). The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls,benign and borderline tumor(P<0.001 or P<0.01). The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues (P<0.0001,P<0.001,and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues(P<0.05). Concluion IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3,which may result in altered bioavailability of IGF-Ⅱ in ovarian cancer,leading to the progress of tumor. The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristics of ovarian cancer patients. Our findings suggest that the presence of new mechanisms in the regulation of IGF-Ⅱ bioavailability,and provide the evidence for the possibility to use IGFBP-2 / IGFBP-3 as biological markers in diagnosis and prognosis of ovarian cancer.更多还原